Skip to content

The effect of ozonated oil on patients with osteoarthritis.

Ozonated oil via topic in degenerative articular disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2szg8b
Enrollment
Unknown
Registered
2018-05-14
Start date
2018-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with osteoarthrosis, older than 50 years. Osteomuscular and connective tissue diseases

Interventions

Participants, in addition to signing the ICF, will respond to a questionnaire containing socio-demographic data to characterize the population, and another questionnaire to assess pain by visual, nume
Drug

Sponsors

Universidade de Passo Fundo
Lead Sponsor
Universidade de Passo Fundo
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients over 50 years of age; Patients who self report having the diagnosis of osteoarthritis.

Exclusion criteria

Exclusion criteria: Patients who have severe cognitive disorders;cancer patients; hospital discharge for less than 30 days; or indigenous people; or have, in addition to osteoarthritis, another chronic inflammatory disease will affect the laboratory results of this research.

Design outcomes

Primary

MeasureTime frame
This work is expected to confirm the benefits of topical ozonated oil in the treatment of osteoarthritis. This test will be done by means of a significant decrease of p <0.05 in pre and post-intervention laboratory tests, WOMAC scale and visual pain scale, applied every 15 days during the intervention.

Secondary

MeasureTime frame
How old the ozonated oil was most effective; this outcome will be evaluated by comparing the data using as the main variable the age and after seeing which group had the largest decrease in pre and post-intervention laboratory tests and a more effective clinical improvement (evaluating the WOMAC scale and visual pain scale each 15 days during the intervention).

Countries

Brazil

Contacts

Public ContactAna ;Charise Anzolin;Bertol

Universidade de Passo Fundo;Universidade de Passo Fundo

anapaulasordianzolin@gmail.com;charise@upf.br5554999686181;5505433169999

Outcome results

None listed

Source: REBEC (via WHO ICTRP)